FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to new cytotoxic agent conjugates; it can be used in medicine. The invention allows for the production of a conjugate of an antibody specifically binding to human CKIT or its antigen-binding fragment with a cytotoxic agent selected from auristatin, amanitin, maitanzinoid, or saporin. Such a conjugate does not induce degranulation of mastocytes and is suitable for destruction of hematopoietic stem cells, for example, in different hereditary immune deficiency diseases, autoimmune disorders, hematopoiesis disorder, or in congenital metabolic disorder. The invention can also be used in medicinal practice for the prevention of immunological rejection of a graft in allogenic transplantation of hematopoietic stem cells.
EFFECT: obtaining a conjugate for destruction of hematopoietic stem cells.
39 cl, 11 ex, 8 tbl, 13 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDE LINKER FOR PRODUCTION OF MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2776302C2 |
| ENGINEERED MULTI-SPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS IN THE CH2-CH3 REGION | 2018 |
|
RU2804031C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTIBODIES TO PAC1 AND THEIR APPLICATION OPTIONS | 2019 |
|
RU2781553C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
